Please login to the form below

Not currently logged in

GSK paid $1bn to settle Paxil lawsuits

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993. Analysts have said the amount is higher than what was expected.

The total paid by the UK's largest pharmaceutical company includes around $390m for cases regarding suicides or attempted suicides reportedly linked to the drug; a further $200m to settle lawsuits of addiction and birth defects; and $400m over antitrust and fraud claims.

However, the $1bn does not include the additional 600+ outstanding claims that Paxil caused birth defects. Only 10 such cases have been settled, at an average cost of $4m to GSK. In one case, settled in October 09, GSK was ordered to pay $2.5m in compensatory damages. Based on these figures, the company may face an additional liability of around $1.5bn.

GSK has declined to confirm the $1bn figure. Spokesperson Sarah Alspach said: "Paxil has been on the market in the US since 1993. Like many other pharmaceutical products, it has been the subject of different kinds of litigation over the years. It would be inappropriate and potentially misleading to aggregate payments in these various types of litigation."

15th December 2009


COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...